{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:14:35Z","timestamp":1791922475034,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.leukres.2022.106920","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T22:59:10Z","timestamp":1658185150000},"page":"106920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Targeting cyclin-dependent kinases 4\/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia"],"prefix":"10.1016","volume":"120","author":[{"given":"Kunming","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangru","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106920_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/leu.2012.223","article-title":"Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children\u2019s Oncology Group Study POG 9421","volume":"27","author":"O\u2019Brien","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106920_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatricnon-down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat. Genet"},{"key":"10.1016\/j.leukres.2022.106920_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.20951","article-title":"Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children\u2019s Oncology Group","volume":"49","author":"Barnard","year":"2007","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.leukres.2022.106920_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in themegakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat. Genet"},{"key":"10.1016\/j.leukres.2022.106920_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/90054","article-title":"Fusion of two novel genes, RBM15 and MKL1, in the t (1;22)(p13;q13) of acute megakaryoblastic leukemia","volume":"28","author":"Ma","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2022.106920_bib6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2022.106920_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/gcc.1208","article-title":"Recurrence of OTT-MAL fusion in t(1;22) of infant AML-M7","volume":"33","author":"Mercher","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2022.106920_bib8","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.3390\/ijerph18147582","article-title":"Clinical and laboratory features of JAK2 V617F, CALR, and MPL mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN)","volume":"18","author":"Zulkeflee","year":"2021","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.leukres.2022.106920_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.leukres.2022.106920_bib10","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2008-11-163501","article-title":"Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome","volume":"113","author":"Malinge","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/pin.12043","article-title":"Clinicopathological features of acute megakaryoblastic leukaemia: relationship between fibrosis and platelet-derived growth factor","volume":"63","author":"Niino","year":"2013","journal-title":"Pathol. Int"},{"key":"10.1016\/j.leukres.2022.106920_bib12","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.3390\/cancers7040903","article-title":"Acute myeloid leukemia with isolated trisomy 19 associated with diffuse myelofibrosis and osteosclerosis","volume":"7","author":"Stelling","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106920_bib13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-015-2383-2","article-title":"Improved outcome of pediatric patients with acute acutemegakaryoblastic leukemia in the AML-BFM 04 trial","volume":"94","author":"Schweitzer","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2022.106920_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/pbc.22943","article-title":"Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: report from the Japanese Children\u2019s cancer and leukemia study group (JCCLSG) AML 9805 down study","volume":"57","author":"Taga","year":"2011","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.leukres.2022.106920_bib15","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.clml.2018.12.011","article-title":"Outcome of childhood acute megakaryoblastic leukemia: Children\u2019s CancerHospital Egypt 57357 experience","volume":"19","author":"Maarouf","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2022.106920_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/gcc.22444","article-title":"Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-down Syndrome","volume":"56","author":"Hara","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2022.106920_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2004-03-1103","article-title":"Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European group for blood and marrow transplantation (EBMT)","volume":"105","author":"Garderet","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41408-017-0031-x","article-title":"ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia","volume":"7","author":"Sun","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2022.106920_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","article-title":"Integrative screening approach identifies regulators of polyploidization and targets for acute megakaryocytic leukemia","volume":"150","author":"Wen","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2022.106920_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers7010179","article-title":"Targeting Cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors","volume":"7","author":"Peyressatre","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2022.106920_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/BLC-170105","article-title":"CDK4\/6 inhibitors in cancer therapy: a novel treatement strategy for bladder cancer","volume":"3","author":"Pan","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.leukres.2022.106920_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1091\/mbc.7.2.209","article-title":"Novel alterations in CDK1\/cyclin B1 kinase complex formation occur during the acquisition of a polyploid DNA content","volume":"7","author":"Datta","year":"1996","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.leukres.2022.106920_bib23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1053\/ajkd.2001.28616","article-title":"Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2\/STAT5 pathway and Cyclin D1","volume":"38","author":"Guh","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.leukres.2022.106920_bib24","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3892\/mmr.2015.4705","article-title":"Protein inhibitor of activated STAT x\u03b1 depresses Cyclin D and Cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression","volume":"13","author":"Wang","year":"2016","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.leukres.2022.106920_bib25","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1182\/blood-2006-11-059378","article-title":"Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization","volume":"109","author":"Muntean","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib26","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1182\/blood.V75.6.1252.1252","article-title":"In vitro establishment and characterization of a human megakaryoblastic cell line","volume":"75","author":"Fugman","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.1989.tb07681.x","article-title":"Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down\u2019s syndrome patient with acute megakaryoblastic leukaemia","volume":"72","author":"Sato","year":"1989","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106920_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1365-2141.2000.02027.x","article-title":"The management of neoplastic disorders of haematopoiesis in children with Down\u2019s syndrome","volume":"110","author":"Lange","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106920_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/08880018709141272","article-title":"Megakaryoblastic leukemia and Down\u2019s syndrome: a review","volume":"4","author":"Zipursky","year":"1987","journal-title":"Pedia Hematol. Oncol."},{"key":"10.1016\/j.leukres.2022.106920_bib30","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood.V71.4.992.992","article-title":"Aclacinomycin A anD Etoposide (VP-16-213): an effective regimen in previously treated patients with Refractory acute myelogenous leukemia","volume":"71","author":"Rowe","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2017.187153","article-title":"Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric Relapsed\/Refractory acute myeloid leukemia: a phase IB study","volume":"103","author":"Van Eijkelenburg","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2022.106920_bib32","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1111\/bph.14031","article-title":"Tetrandrine antagonizes acute megakaryoblastic leukaemia growth by forcingautophagy-mediated differentiation","volume":"174","author":"Liu","year":"2017","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.leukres.2022.106920_bib33","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora Kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2022.106920_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0275-0","article-title":"Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and golgi-mediated secretion","volume":"9","author":"Han","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2022.106920_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13578-016-0084-8","article-title":"Baicalein antagonizes acute megakaryoblastic leukemia in vitro and in vivo by inducing cell cycle arrest","volume":"6","author":"Yu","year":"2016","journal-title":"Cell Biosci."},{"key":"10.1016\/j.leukres.2022.106920_bib36","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2015-11-683581","article-title":"Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6","volume":"127","author":"Uras","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib37","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2015.353","article-title":"CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia","volume":"30","author":"Jena","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106920_bib38","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/ijc.33054","article-title":"The role of CDK6 in cancer","volume":"147","author":"Nebenfuehr","year":"2020","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.leukres.2022.106920_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2014-02-558114","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003267","article-title":"CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia","volume":"136","author":"Schmoellerl","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106920_bib41","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ccell.2018.08.015","article-title":"The oncogenic transcription factor RUNX1\/ETO corrupts cell cycle regulation to drive leukemic transformation","volume":"34","author":"Martinez-Soria","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2022.106920_bib42","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.3390\/ijms19123987","article-title":"Therapeutic vulnerabilities in FLT3-mutant AML unmasked by Palbociclib","volume":"19","author":"Uras","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.leukres.2022.106920_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13578-016-0084-8","article-title":"Baicalein antagonizes acute megakaryoblastic leukemia in vitro and in vivo by inducing cell cycle arrest","volume":"6","author":"Yu","year":"2016","journal-title":"Cell Biosci."},{"key":"10.1016\/j.leukres.2022.106920_bib44","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(-) metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2022.106920_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","article-title":"CDK4\/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, Ribociclib and Abemaciclib","volume":"33","author":"Eggersmann","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.leukres.2022.106920_bib46","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/genes12091355","article-title":"Targeting the CDK6 dependence of Ph+ acute lymphoblastic leukemia","volume":"12","author":"Porazzi","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.leukres.2022.106920_bib47","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity","volume":"26","author":"Hafner","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.leukres.2022.106920_bib48","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/leu.2013.33","article-title":"AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL","volume":"27","author":"Stankiewicz","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106920_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918793326","article-title":"Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer","volume":"10","author":"Thill","year":"2018","journal-title":"Ther. Adv. Med Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:53Z","timestamp":1758934973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":49,"alternative-id":["S0145212622001461"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106920","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cyclin-dependent kinases 4\/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106920"}}